In November 2025, the FDA announced it would remove the boxed warnings — the "black box" warnings — from menopausal hormone therapy products containing estrogen. For women who were told two decades ago that hormone therapy was dangerous, this is a significant reversal, and it has generated real confusion. Here is what changed, what did not, and what it means for you.
On November 10, 2025, the FDA announced it would remove the boxed warnings from estrogen-containing hormone therapy products. The agency began working with manufacturers to update labeling to remove references to risks of cardiovascular disease, breast cancer, and probable dementia.
Two details matter and are frequently lost in coverage.
First, the boxed warning for endometrial cancer remains in place for products containing systemic estrogen alone. It was not removed. This is precisely why estrogen is paired with a progestogen in women who still have a uterus.
Second, updated labels are expected to carry age-specific guidance reflecting evidence that women may see long-term benefit when hormone therapy is initiated within roughly ten years of the onset of menopause. Timing is now part of the official framing rather than an asterisk.
The warnings trace to the Women's Health Initiative, a large trial whose initial results in 2002 were widely reported as showing that hormone therapy increased risks of breast cancer, heart disease, and stroke. Prescribing collapsed almost overnight. An entire generation of women was steered away from treatment, and an entire generation of clinicians was trained to be wary of it.
The reanalysis over the following two decades complicated that picture considerably. The average participant was in her early sixties — many were more than a decade past menopause. That turns out to matter enormously. The trial also studied specific formulations and delivery routes that are not the ones most commonly prescribed today. Applying findings from that population to a healthy 51-year-old with hot flashes was an extrapolation that the data did not really support.
This is a case of medicine correcting itself with better analysis. It is worth understanding that history, because it explains why your mother may have been told the exact opposite of what you are being told now.
No, and this is the part most likely to be misread.
Removing a boxed warning is a change to how risk is communicated. It is not a declaration that risk is zero, and it is not a recommendation that every woman take hormones. Hormone therapy still has genuine contraindications. A history of certain hormone-sensitive cancers, unexplained vaginal bleeding, active liver disease, or a history of blood clots or stroke all require careful individual evaluation, and in some cases mean hormone therapy is not appropriate at all.
What changed is the default posture. For a healthy woman within about ten years of menopause with bothersome symptoms, the risk-benefit calculation now more often favors treatment than the old labeling implied. That is a meaningful shift. It is not a blanket clearance, and any clinic treating it as one is doing you a disservice.
Hormone therapy has strong evidence for relieving vasomotor symptoms — hot flashes and night sweats — and for genitourinary symptoms of menopause including vaginal dryness, discomfort with intercourse, and some urinary symptoms. It is also established for the prevention of postmenopausal osteoporosis.
Many women also report improvements in sleep, mood, and cognitive clarity. Some of that is likely a direct effect and some is the downstream result of no longer waking up five times a night drenched in sweat. Both are worth having.
What hormone therapy is not is a general anti-aging protocol or a weight loss treatment. It treats the symptoms of hormonal transition. That is a substantial and worthwhile thing for it to do.
Yes, and the shift predates the label change. Analyses of prescribing data show estrogen-based hormone therapy use more than doubled between 2018 and 2026, with prescribing among women aged 45 to 54 rising by roughly 184 percent over that period. By February 2026, about one in twenty women in that age group had evidence of an estrogen-based prescription.
The route of delivery is also shifting. The largest increases have been in patches and vaginal creams — patch use more than tripled, and vaginal cream use rose more than fourfold. That trend reflects growing clinical preference for transdermal and local delivery in appropriate candidates.
Notably, much of this movement was driven by patients. Clinicians increasingly report that women raise hormone therapy before the provider does.
Perimenopause — the transition leading up to your final period — can last for years and is where many women are most symptomatic and least well served. Cycles become irregular, hormones fluctuate rather than simply declining, and symptoms can be erratic and difficult to attribute.
The common frustration is being told you are "too young" or that your labs are "normal." During perimenopause a single hormone panel can be misleading, because levels swing substantially from week to week. A normal reading on a Tuesday does not mean much. This is a phase where symptoms and history carry more diagnostic weight than an isolated lab value, and where being listened to matters.
No. The FDA moved to remove boxed warnings related to cardiovascular disease, breast cancer, and probable dementia. The boxed warning for endometrial cancer remains for systemic estrogen-only products.
The evidence most strongly favors initiation within about ten years of the onset of menopause or before age 60. Starting later does not automatically rule it out, but the risk-benefit balance shifts and requires more individualized evaluation. This is a conversation to have with a provider rather than a rule to apply to yourself.
"Bioidentical" describes molecular structure, not safety or efficacy. FDA-approved products containing bioidentical hormones such as estradiol are regulated and tested. Custom-compounded bioidentical preparations are not held to the same standards for potency and purity, and major medical organizations have generally not endorsed them over approved products.
Hormone therapy is not a weight loss treatment. Some women find that improved sleep and symptom relief make other efforts more sustainable, but hormone therapy should not be prescribed or pursued for weight loss.
The older guidance of "lowest dose for the shortest time" has softened considerably as the evidence has been reexamined. Duration is now individualized based on your symptoms, risk profile, and preferences, and revisited over time rather than fixed at the outset.
If you were told years ago that hormone therapy was off the table, that advice was based on an interpretation of the evidence that has since changed substantially. It is reasonable to revisit it. It is also reasonable to expect a real evaluation rather than a reflexive yes or no.
To talk through whether hormone optimization makes sense for your symptoms, history, and goals, call Alpine Health & Wellness in Kalispell, MT at 406-361-7421. Our provider team will review your history, run appropriate labs, and give you a clear recommendation — including when the answer is that hormone therapy is not right for you.
This article is for general educational purposes and does not constitute medical advice. It does not establish a provider-patient relationship. Hormone therapy carries risks and contraindications and is not appropriate for everyone. Regulatory statements reflect FDA announcements as of July 2026, and labeling implementation is ongoing. Please consult a qualified healthcare provider about your individual circumstances before starting or stopping any therapy.
